SIRPA and ovarian carcinoma: Monotherapy involving the blockade of the CD47-SIRPα axis has shown promising outcomes in ovarian cancer, with the combination of pro-phagocytic CD47-SIRPα axis monoclonal antibodies and Fc-dependent effects of tumor-targeting antibodies, such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), demonstrating synergistic efficacy (10, 24).